E V Bril, A A Tomskiy, A A Gamaleya, A A Poddubskaia, D G Kesarev, S M Omarova, N V Fedorova, O S Levin
{"title":"[DBS STN背景下帕金森病的病理形态]。","authors":"E V Bril, A A Tomskiy, A A Gamaleya, A A Poddubskaia, D G Kesarev, S M Omarova, N V Fedorova, O S Levin","doi":"10.17116/jnevro202512502121","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To study the clinical pathomorphosis of Parkinson's disease (PD) against the background of stimulation of the subthalamic nucleus (DBS STN).</p><p><strong>Material and methods: </strong>: We present a 15-year analysis of 401 patients with PD in two groups: DBS STN (<i>n</i>=233) and drug therapy group (<i>n</i>=168). In order to study the clinical pathomorphism of the disease, an analysis of the dynamics of the main motor symptoms of PD was carried out using the UPDRS scale, as well as an analysis of the survival of patients in both groups.</p><p><strong>Results: </strong>DBS STN significantly improved motor symptoms in patients with PD during the off period by 57.3% by year 1, by 23.7% by year 15. According to this indicator, patients did not reach the preoperative level. During the inclusion period in this group, the improvement was 40%, the indicator remained stable for 3 years, however, due to the progression of the disease, by the 15<sup>th</sup> year the deterioration was 20.9%. In the group of patients receiving only drug therapy, there was a progressive worsening of motor symptoms in the off period by 67.5% by the 15<sup>th</sup> year of observation, in the on period 64.5% (<i>p</i><0.05). Univariate survival analysis showed that patients receiving STN-DBS had significantly longer survival than those receiving medical treatment alone (<i>p</i>=0.008).</p><p><strong>Conclusion: </strong>DBS STN changes the clinical pathomorphosis of Parkinson's disease, leading to less severity of parkinsonian symptoms and greater survival of this group of patients.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 2","pages":"21-27"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Pathomorphosis of the Parkinson's disease against the background of DBS STN].\",\"authors\":\"E V Bril, A A Tomskiy, A A Gamaleya, A A Poddubskaia, D G Kesarev, S M Omarova, N V Fedorova, O S Levin\",\"doi\":\"10.17116/jnevro202512502121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To study the clinical pathomorphosis of Parkinson's disease (PD) against the background of stimulation of the subthalamic nucleus (DBS STN).</p><p><strong>Material and methods: </strong>: We present a 15-year analysis of 401 patients with PD in two groups: DBS STN (<i>n</i>=233) and drug therapy group (<i>n</i>=168). In order to study the clinical pathomorphism of the disease, an analysis of the dynamics of the main motor symptoms of PD was carried out using the UPDRS scale, as well as an analysis of the survival of patients in both groups.</p><p><strong>Results: </strong>DBS STN significantly improved motor symptoms in patients with PD during the off period by 57.3% by year 1, by 23.7% by year 15. According to this indicator, patients did not reach the preoperative level. During the inclusion period in this group, the improvement was 40%, the indicator remained stable for 3 years, however, due to the progression of the disease, by the 15<sup>th</sup> year the deterioration was 20.9%. In the group of patients receiving only drug therapy, there was a progressive worsening of motor symptoms in the off period by 67.5% by the 15<sup>th</sup> year of observation, in the on period 64.5% (<i>p</i><0.05). Univariate survival analysis showed that patients receiving STN-DBS had significantly longer survival than those receiving medical treatment alone (<i>p</i>=0.008).</p><p><strong>Conclusion: </strong>DBS STN changes the clinical pathomorphosis of Parkinson's disease, leading to less severity of parkinsonian symptoms and greater survival of this group of patients.</p>\",\"PeriodicalId\":56370,\"journal\":{\"name\":\"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova\",\"volume\":\"125 2\",\"pages\":\"21-27\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17116/jnevro202512502121\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/jnevro202512502121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Pathomorphosis of the Parkinson's disease against the background of DBS STN].
Objectives: To study the clinical pathomorphosis of Parkinson's disease (PD) against the background of stimulation of the subthalamic nucleus (DBS STN).
Material and methods: : We present a 15-year analysis of 401 patients with PD in two groups: DBS STN (n=233) and drug therapy group (n=168). In order to study the clinical pathomorphism of the disease, an analysis of the dynamics of the main motor symptoms of PD was carried out using the UPDRS scale, as well as an analysis of the survival of patients in both groups.
Results: DBS STN significantly improved motor symptoms in patients with PD during the off period by 57.3% by year 1, by 23.7% by year 15. According to this indicator, patients did not reach the preoperative level. During the inclusion period in this group, the improvement was 40%, the indicator remained stable for 3 years, however, due to the progression of the disease, by the 15th year the deterioration was 20.9%. In the group of patients receiving only drug therapy, there was a progressive worsening of motor symptoms in the off period by 67.5% by the 15th year of observation, in the on period 64.5% (p<0.05). Univariate survival analysis showed that patients receiving STN-DBS had significantly longer survival than those receiving medical treatment alone (p=0.008).
Conclusion: DBS STN changes the clinical pathomorphosis of Parkinson's disease, leading to less severity of parkinsonian symptoms and greater survival of this group of patients.
期刊介绍:
Одно из старейших медицинских изданий России, основанное в 1901 году. Создание журнала связано с именами выдающихся деятелей отечественной медицины, вошедших в историю мировой психиатрии и неврологии, – С.С. Корсакова и А.Я. Кожевникова.
Широкий диапазон предлагаемых журналом материалов и разнообразие форм их представления привлекают внимание научных работников и врачей, опытных и начинающих медиков, причем не только неврологов и психиатров, но и специалистов смежных областей медицины.